



Tairawhiti DHB 1 Jan - 31 Dec 2021

% susceptible
clinical isolates,
screening not
included

	<i>S. aureus</i> (sterile sites)	<i>S. aureus</i> (non-sterile sites)	MRSA	Coagulase negative Staphylococci (blood)#	<i>Staph saprophyticus</i> (urine)	<i>Strep. pneumoniae</i> #	<i>Enterococcus</i> spp	<i>Haemophilus influenzae</i>	<i>Pseudomonas aeruginosa</i>	<i>E. coli</i> (blood)	<i>E. coli</i> (urine)	<i>E. coli</i> ESBL (urine)	<i>Klebsiella</i> species
Approx No. Tested	50	1300	130	60#	340	40#	140	70	220	40	1300	55	90-140
Amoxicillin			R			87	95	57	R			R	R
Amox/Clav			R					71	R	51	85**		88**
Cefalexin***			R				R		R		95	R	93
Cefepime			R				R		93			R	
Ceftazidime			R				R		96			R	
Ceftriaxone			R			Insuff	R	100	R	97		R	93
Cefuroxime			R				R		R	97		R	Insuff
Clindamycin	90	92	88	76									
Cotrimoxazole		98	93		100	64	R	63	R				95
Erythromycin		90	81			93							
Flucloxacillin	90	90	R	67	88		R						
Fluoroquinolones							R		92	89	92	52	96
Fusidic Acid		88	64				R						
Gentamicin										93		75	98
Meropenem			R						97	100		100	100
Nitrofurantoin***					100		97*				99	91	
Penicillin			R			Insuff							
Pip/Taz			R						96	91			89
Tetracycline		98	93			95		100					
Tobramycin									96	93			98
Trimethoprim***					100						75	46	94
Vancomycin	100	100	100	100			100						
ESBL+ve -% of total										0%	2%		1%
AmpC+ve -% of total										0%	2%		0%
Carbapenemase+ve % of total									0%	0%	0%		0%

≥ 90% of isolates susceptible
 70 - 90% of isolates susceptible
 Insuff
 Insufficient isolates (<30)

< 70% of isolates susceptible
 R
 Intrinsically Resistant

Isolates reported as "Susceptible, increased exposure" are now regarded as part of the Susceptible group.

Isolates for 2020 and 2021 included to reach >30 isolates

* *Enterococcus faecalis* only, no breakpoints available for *Enterococcus faecium*

** Refers to uncomplicated UTI